Paxlovid is safe for most adults at high risk of severe COVID-19, and it has been FDA-approved since 2023 for that purpose. The main safety concern isn’t the drug itself but how it interacts with other medications you may already be taking. That interaction profile is unusually broad, which is why your prescriber needs a complete list of your current medications before writing a prescription.
Who Paxlovid Is Designed For
Paxlovid is approved for adults 18 and older with mild-to-moderate COVID-19 who are at high risk of progressing to severe illness, hospitalization, or death. Risk factors include being overweight (BMI above 25), having diabetes, heart disease, chronic lung conditions, or a weakened immune system, among others. The drug is not intended for people with mild COVID who are otherwise healthy and at low risk of complications.
Treatment is a five-day course: two tablets of nirmatrelvir (150 mg each) plus one tablet of ritonavir (100 mg), all taken together twice a day. You need to start within five days of your first symptoms for the drug to work effectively. The sooner you begin, the better the outcomes.
Why Drug Interactions Are the Biggest Safety Issue
Paxlovid contains two active ingredients. One, nirmatrelvir, attacks the virus directly. The other, ritonavir, doesn’t fight COVID at all. Its job is to slow your liver’s ability to break down nirmatrelvir, keeping antiviral levels high enough to be effective. The problem is that ritonavir also slows the breakdown of many other medications, causing their levels to spike in your bloodstream, sometimes to dangerous or even life-threatening concentrations.
The list of contraindicated drugs is long and spans several categories:
- Heart rhythm medications such as amiodarone, flecainide, and propafenone
- Cholesterol-lowering statins like lovastatin and simvastatin
- Seizure medications including carbamazepine, phenytoin, and phenobarbital (these actually reduce Paxlovid’s effectiveness rather than becoming toxic)
- Certain antipsychotics such as lurasidone and pimozide
- Immunosuppressants including voclosporin
- Tuberculosis drugs like rifampin
This is not an exhaustive list. Dozens of medications interact with ritonavir, and some interactions can be managed by temporarily adjusting doses while others are absolute no-gos. If you take any prescription medications regularly, your prescriber will need to check each one before clearing you for Paxlovid. This is especially relevant for older adults, who are both more likely to qualify for Paxlovid and more likely to be on multiple medications.
Kidney and Liver Considerations
Your kidney function determines whether you can take Paxlovid and at what dose. People with mild kidney impairment (an eGFR of 60 or above) take the standard dose with no changes. If your kidney function is moderate (eGFR between 30 and 60), the nirmatrelvir dose is cut in half to 150 mg while the ritonavir stays at 100 mg. If your eGFR is below 30, Paxlovid is not recommended because no safe dose has been established for that level of kidney impairment.
For liver function, people with mild or moderate liver disease can take the standard dose. Paxlovid is contraindicated in severe liver disease because there is no safety data for that population.
Paxlovid Rebound
Some people finish their five-day course, feel better, and then experience a return of symptoms a few days later. This is commonly called “Paxlovid rebound,” and it understandably raises concerns. But research suggests rebound isn’t unique to the drug. A large observational study found rebound occurred in about 6.6% of Paxlovid-treated patients, compared to 4.5% of untreated patients, a difference that was not statistically significant. Some studies have put the rebound rate for treated patients somewhat higher, in the 10% to 14% range.
The reassuring finding is that rebound cases are mild. No hospitalizations or deaths were reported among outpatients who experienced rebound. Symptoms resolved quickly on their own. The CDC’s review of the evidence concluded that for people at risk of severe disease, the substantial benefit of antiviral treatment outweighs the risk of rebound.
Safety During Pregnancy and Breastfeeding
Both the CDC and the American College of Obstetricians and Gynecologists recommend against withholding Paxlovid from pregnant or breastfeeding individuals solely because of their pregnancy or lactation status. ACOG actually lists Paxlovid as the preferred outpatient treatment for pregnant people with COVID-19, since pregnancy itself raises the risk of severe illness. The standard five-day dosing applies, though prescribers still need to review for drug interactions just as they would for any other patient.
Common Side Effects
The most frequently reported side effect is a metallic or bitter taste in the mouth, sometimes described as a persistent unpleasant flavor that lasts through the treatment course. Diarrhea and nausea are also common but generally mild. These side effects resolve once you finish the five-day course and are not considered dangerous. For most people, the experience of taking Paxlovid is straightforward: an unpleasant taste for a few days in exchange for a significantly lower chance of ending up in the hospital.